PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. (Q30381763)

21 June 2017

PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. (English)

1 reference

21 June 2017

0 references

4

Tetsutaro Sata

1 reference

21 June 2017

5

Hideki Hasegawa

1 reference

21 June 2017

Takeshi Ichinohe

1

1 reference

21 June 2017

Akira Ainai

series ordinal

2

1 reference

21 June 2017

Masato Tashiro

series ordinal

3

1 reference

21 June 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

21 June 2017

1 reference

21 June 2017

27

1 reference

21 June 2017

6276-6279

1 reference

21 June 2017

45

1 reference

Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.074

Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.074

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.074

Toll-like receptor control of the adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.074

A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.074

Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.074

Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.074

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.074

Innate sensors of influenza virus: clues to developing better intranasal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.074

TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.074

Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.074

Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.074

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.04.074

1 reference

21 June 2017

1 reference